GoggleDocs

🥽🩺Docs/nurses/pharmacists from U.K. Talking CardioRenoMetabolic & more Catch us on YouTube |Educate, Motivate, Activate!

[Professor Kamlesh Khunti @kamleshkhunti]

CGM may have an important role in type 2 diabetes even for people who are not using insulin.
@NEJM

In this 26-week primary care RCT of 283 adults:
📉 HbA1c: 7.2% with CGM vs 8.0% with routine care

⏱️ Time in range: +21 percentage points

✅ No severe hypoglycaemia reported

For patients: seeing glucose responses in real time may help connect food, activity and treatment with glucose levels.

Need robust data on cost-effectiveness and in which patient population with T2 diabetes

@AskDrShashank

[GoggleDocs @GoggleDocs]

@AmarPut @drkevinfernando @drpatrickholmes @scelee1 @DSNforumUK @HannahBeba @CristobMorales @NICEComms 💯

[GoggleDocs @GoggleDocs]

💉 Once-weekly basal insulin is here. MHRA has authorised Onswik (efsitora) for #T2D

🏛️NICE: an option, but use the least expensive suitable basal, NPH included. Likely role: people who need help to inject.

UK price confidential. Awaiting final TA + ICB pathways.

🔗https://t.co/NWqFJzuDrt

🔗https://t.co/4DDmgmz7Oq

[Dr Amar Puttanna 🎸 @AmarPut]

@GoggleDocs @drkevinfernando @drpatrickholmes @scelee1 @DSNforumUK @HannahBeba @CristobMorales @NICEComms expects benefit in a frail, vulnerable cohort…. Show me the evidence… potential for harm has not been mitigated and needs to be balanced/addressed…

[Professor Kamlesh Khunti @kamleshkhunti]

🧓 Can GLP-1 RAs help preserve function in people with diabetes?

In 73,592 propensity-matched pairs, GLP-1 RA initiation vs DPP-4 inhibitors was associated with:

📉 Less frailty progression
🚶 13% lower fall rate (IRR 0.87, 95% CI 0.84–0.91)
⚠️ Associations were weaker in severe baseline frailty.

Real-world evidence, not proof of causality.
#Diabetes #Frailty #GLP1RA #Geriatrics

https://t.co/IFi5QDrjKE

@AskDrShashank

[Professor Kamlesh Khunti @kamleshkhunti]

🩺 HbA1c vs fasting glucose: Which better predicts cardiometabolic multiple long term conditions (multimorbidity) in people without diabetes?

Our study led by @scelee1 & Setor

In 2,233 adults in England followed for 12–15 years, both markers were associated with future cardiometabolic multimorbidity—but HbA1c was the stronger predictor.

📈 Each 1% higher HbA1c: ~2× higher odds

🔬 HbA1c improved risk discrimination more than fasting glucose.

HbA1c help identify long-term cardiometabolic risk earlier?

#Diabetes #CardiometabolicHealth #Prevention #PublicHealth

https://t.co/wfRhO8NKxw

@AskDrShashank @LDC_tweets @uniofleicester

[Neil Floch MD @NeilFlochMD]

GLP-1 are a life changing and possibly a humanity changing group of medications. The fact that insurance will not cover them should cause patients to be extremely angry.

Obesity is the mother of chronic disease.

Successful obesity treatment should not be discriminated against.

[Brendon Neuen @brendonneuen]

Colleagues, we need your help -

We're seeking nephrologists' perspectives on management of iron deficiency in CKD. The survey takes <5 minutes & will help shape the design of a new international randomised trial

https://t.co/T9G4ILLL70

Thanks for sharing with your networks

[Dr. Shashank Joshi @AskDrShashank]

Next-Generation Obesity and Diabetes Therapy

CagriSema — REIMAGINE 2
HbA1c reduction: 1.9%
Weight reduction: 14.6%
TIR increased from 52.3% to 88.0% at week 68

Retatrutide — TRIUMPH-2
Major weight reduction with accompanying improvement in glycaemic control.

Survodutide — SYNCHRONIZE-2
-Significant weight loss and HbA1c reduction, -gastrointestinal adverse effects ( concerning point)

Amylin-Based Therapies
-An emerging major pathway for obesity treatment, -cagrilintide and eloralintide.

Oral Incretin Therapies
-oral semaglutide
-orforglipron.

Once-Weekly Basal Insulin

[GoggleDocs @GoggleDocs]

🚨Retatrutide TRIUMPH-1 (NEJM)

80 wk weight: ⤵️25% on 12 mg vs -3.9% placebo.
⤵️28.3% headline = efficacy estimand.

👉9 vs 12 mg near identical; only 54% still on 12 mg at wk 80
⚠️⚡️Dysaesthesia, hypotension, MACE 9 v 1 (small n)

Treat to target, not max dose❓

🔗 https://t.co/EzUfsILnYI

[1990sUtd @1990sUtd]

Marvellous edit 😅

[GoggleDocs @GoggleDocs]

🚨#Tirzepatide and AF: signal or noise? 🫀

🆕 JAHA meta-analysis (10 RCTs, n=6,515): AF OR 2.20 (0.81–6.75), any arrhythmia OR 1.84 (1.04–3.90)

🔹Only 38 AF events, mostly from SUMMIT

🔸Semaglutide: 541 events, OR 0.83 (0.70–0.98)

👉Different class, different signal❓

🔗https://t.co/9fPvdiHoph
🔗https://t.co/Awmqqp7NwM

[Don McGowan @donmcgowan]

Dear @Ofcom

Please can you clarify to the nation why this is allowed under your current broadcasting rules?

A sitting MP [sometimes] on a TV channel he part owns, delivering a party political broadcast on behalf of Reform UK?

Seriously ... WTF?

[Patrick Holmes @drpatrickholmes]

🆕NICE guidelines

Arguably the biggest shift in #type2diabetes care in over a decade.

Phenotype first. HbA1c second.

@drkevinfernando & I are running a free hour on what it actually changes in clinic.

Thu 10 Sept, 7-8pm BST

No industry funding

🔗https://t.co/hkZ3HZwPzv

[Dr Amar Puttanna 🎸 @AmarPut]

Excited to work with @ATTDconf

👉🏽Management of older adults, technology & diabetes👈🏽

❓How do we manage older adults with diabetes
❓How do we balance intervention with support and QOL
❓What is the role of technology & how can we simplify/facilitate

https://t.co/Twp9ju8U4B

[GoggleDocs @GoggleDocs]

@scivier_martin @AmarPut @ATTDconf @EASDnews @AmDiabetesAssn @ABCDiab @IntDiabetesFed @dramitaol @AliceYYCheng @JGolding_1 @AskDrShashank @banshisaboo It’s a webinar I believe

[Brendon Neuen @brendonneuen]

“CKD is not really a disease… trials don’t necessarily translate to living longer”

Not really sure where to start here. But trials in the last 20 years in which CKD therapies extend survival:

#DAPACKD HR 0.69 (0.53-0.88)
#FIDELITY HR 0.89 (0.79-1.00)
#FLOW HR 0.80 (0.67-0.95)

[GoggleDocs @GoggleDocs]

#ESCcongress2025

💊 STAREE in NEJM: atorvastatin 40mg vs placebo, 9,971 adults aged 70+, 5.9 yrs

📉 Major CV events HR 0.70 ✅ NNT 37
⚖️ Disability-free survival HR 0.94 (0.84–1.05) ❌
📊 CV death HR 1.00

Fewer heart attacks. Not a longer or more independent life

[Ketan Dhatariya @ketandhatariya]

Interviewed by the @NakedScientists on diabetes related foot wounds @Franers13 @iwgdf @gooday_c https://t.co/rPdmWtIzIq